The expression of CD300LG-γ at mRNA and protein level was detected by semiquantitative reverse transcription-polymerase chain reaction (PCR), quantitative real-time PCR, and western blot, and compared by t-test analysis. The results of semiquantitative reverse transcription-PCR showed that the mRNA expression of CD300LG-γ was significantly lower in pulmonary carcinoma tissues, compared to tumor-adjacent tissues. The results of quantitative real-time PCR confirmed this finding. The mRNA level of CD300LG-γ in pulmonary carcinoma tissues compared with tumor-adjacent tissues was 0.436-fold in a median. The results of western blot indicated that CD300LG-γ protein was expressed in both pulmonary carcinoma and tumor-adjacent tissues, and the expression level was significantly lower in pulmonary carcinoma tissues compared with tumor-adjacent tissues. Both mRNA and protein levels of CD300LG-γ in pulmonary carcinoma tissues were significantly lower than that in tumor-adjacent tissues, which might lead to inhibition of killing function of immunocytes, resulting in immune escape of lung cancer cells.
Get full access to this article
View all access options for this article.
References
1.
UmemotoE, HayasakaH, BaiZ, CaiL, YonekuraS, PengX, TakedaA, TohyaK, and MiyasakaM: Novel regulators of lymphocyte trafficking across high endothelial venules. Crit Rev Immunol, 2011; 31:147–169.
2.
UmemotoE, TanakaT, KandaH, JinS, TohyaK, OtaniK, MatsutaniT, MatsumotoM, EbisunoY, JangMH, FukudaM, HirataT, and MiyasakaM: Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. J Exp Med, 2006; 2031603–1614.
3.
RychlyJ, and NebeB: Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des, 2006; 12:3799–3806.
4.
TakatsuH, HaseK, OhmaeM, OhshimaS, HashimotoK, TaniuraN, YamamotoA, and OhnoH: CD300 antigen like family member G: A novel Ig receptor like protein exclusively expressed on capillary endothelium. Biochem Biophys Res Commun, 2006; 348:183–191.
5.
UmemotoE, TakedaA, JinS, LuoZ, NakahogiN, HayasakaH, LeeCM, TanakaT, and MiyasakaM: Dynamic changes in endothelial cell adhesion molecule nepmucin/CD300LG expression under physiological and pathological conditions. PLoS One, 2013; 8:e83681.
6.
BerlinC, BergEL, BriskinMJ, AndrewDP, KilshawPJ, HolzmannB, WeissmanIL, HamannA, and ButcherEC: Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell, 1993; 74:185–195.
7.
JinS1, UmemotoE, TanakaT, ShimomuraY, TohyaK, KunizawaK, YangBG, JangMH, HirataT, and MiyasakaM: Nepmucin/CLM-9, an Ig domain-containing sialomucin in vascular endothelial cells, promotes lymphocyte transen-dothelial migration in vitro. FEBS Lett, 2008; 582:3018–3024.
8.
UmemotoE, KunizawaK, JinS, JangM, PengX, and MiyasakaM: Nepmucin mediates uptake of apoptotic cells in the endothelial cells of high endothelial venules. International Immunology Meeting Abstracts, 2010; 22:ii63.
9.
JiangX, WangH, LiZ, WeiD, YangY, ZhengX, BiJ, and ZhangC: A monoclonal antibody against a novel Sialomucin CD300LG. Monoclon Antib Immunodiagn Immunother, 2013; 32:91–97.
10.
LivakKJ, and SchmittgenTD: The analysis of relative gene expression data using real-time PCR and the policy 2 (Delta, Delta C (T)) Method. Methods, 2001; 25:402–408.
11.
HarleyCB. Telomerase and cancer therapeutics. Nat Rev Cancer, 2008; 8:167–179.
12.
PaulNL, and RuddleNH: Lymphotoxin. Annu Rev Immunol, 1988; 6:407–438.
13.
HeiserA, MauriceMA, YanceyDR, WuNZ, DahmP, PruittSK, BoczkowskiD, NairSK, BalloMS, GilboaE, and ViewegJ: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol, 2001; 166:2953–2960.
14.
ZeytunA, HassunehM, NagarkattiM, and NagarkattiPS: Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street. Blood, 1997; 90:1952–1959.
15.
van den BroekMF1, KägiD, ZinkernagelRM, and HengartnerH: Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol, 1995; 25:3514–3516.
16.
RadfordKJ, TullettKM, and LahoudMH: Dendritic cells and cancer immunotherapy. Curr Opin Immunol, 2014; 27:26–32.
17.
AnagnostouVK, and BrahmerJR: Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res, 2015; 21:976–984.
WangRF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in anti tumor immunity. Trends Immunol, 2001; 22:269–276.
20.
DeNardoDG1, BarretoJB, AndreuP, VasquezL, TawfikD, KolhatkarN, and CoussensLM: CD4 (+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 2009; 16:91–102.
21.
PuddeyIB, ZilkensRR, CroftKD, and BeilinLJ. Alcohol and endothelial function: A brief review. Clin Exp Pharmacol Physiol, 2001; 28:1020–1024.
22.
GutierrezL, MauriatM, PellouxJ, BelliniC, and Van WuytswinkelO: Towards a systematic validation of references in real-time rt-PCR. Plant Cell, 2008; 20:1734–1735.
23.
BustinSA, and MuellerR: Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond), 2005; 109:365–379.
24.
ZhengD, HuaF, MeiC, WanH, and ZhouQ. Association between GSTM1 genetic polymorphism and lung cancer risk by SYBR green I real-time PCR assay. Zhongguo Fei Ai Za Zhi, 2010; 13:506–510.
25.
KaiJ, ShuZ, YinkunL. Alteration of glycan structure and glycoprotein function in cancer. Chin J Clin Med, 2011; 18:885–887.
